Overview
PEPS ranks this pair inside the Top 300 market-cap universe. That means Injective and APEPE are liquid enough for an indexable comparison, with metrics refreshed on the hourly coin pipeline.
Quick winners
Full comparison
| Metric | INJ | APEPE |
|---|---|---|
| Price | $5.15 | $1,880.52 |
| Market Cap | $490.41M | $199.84M |
| FDV | — | — |
| Volume 24h | $2.50M | $3.94M |
| Circulating Supply | — | — |
| Total Supply | — | — |
| Max Supply | — | — |
| Rank | 98.00 | 160.00 |
| Dominance | — | — |
| Liquidity | — | — |
| Volatility | +5.97% | +3.64% |
| ATH | — | — |
| ATL | — | — |
| ROI | — | — |
Performance
| Timeframe | INJ | APEPE |
|---|---|---|
| 1H | — | — |
| 24H | +5.19% | +0.60% |
| 7D | — | — |
| 30D | — | — |
| 90D | — | — |
| 1Y | — | — |
| YTD | — | — |
| ALL | — | — |
Comparative chart
Technical indicators
| Indicator | INJ | APEPE |
|---|---|---|
| RSI | 49.29 | 49.02 |
| MACD histogram | — | — |
| EMA20 | — | — |
| EMA50 | — | — |
| EMA100 | — | — |
| EMA200 | — | — |
| SMA50 | — | — |
| SMA200 | — | — |
| ATR | 0.29 | 67.35 |
| ADX | 12.19 | 21.33 |
| Support | 4.91 | 1,827.82 |
| Resistance | 5.47 | 1,960.30 |
| Trend | neutral | bearish |
| Momentum | — | 63.00 |
| Signal | neutral | neutral |
Automatic technical analysis
Indicator stacks for INJ/APEPE currently lean on separate regimes: neutral versus bearish. Treat MACD and RSI as context, not as standalone entry triggers.
Fundamentals
| Metric | INJ | APEPE |
|---|---|---|
| Consensus | — | — |
| Blockchain | — | — |
| TPS | — | — |
| Block time | — | — |
| Finality | — | — |
| Validators | — | — |
| Staking | — | — |
| TVL | — | — |
| Supply model | — | — |
| Inflation | — | — |
| Developer activity | 0.00 | — |
| Github activity | 118.00 | — |
| On-chain activity | — | — |
| Whale activity | — | — |
| Addresses | — | — |
| Gas fees | — | — |
Ecosystem
Injective
APEPE
Pros and cons
Pros of Injective
- Market-cap scale on Injective may dampen some idiosyncratic shocks versus smaller peers.
- Injective typically benefits from deeper liquidity and broader market recognition inside the Top 300 set.
- Higher ranking for Injective can translate into tighter spreads on major venues.
Cons of Injective
- Data gaps in niche fundamentals still apply — absence of a field is not confirmation.
- Crowded positioning around INJ sometimes amplifies squeeze or flush risk.
- Large-cap status for Injective can mean slower percentage upside versus high-beta alternatives.
Pros of APEPE
- If technical momentum aligns, APEPE may outperform on medium-term windows.
- PEPS tracking for APEPE still includes AI score and level context for monitoring.
- Diversifying versus Injective with APEPE can change portfolio factor exposure.
Cons of APEPE
- Relative underperformance versus Injective can persist through entire market regimes.
- Higher volatility on APEPE cuts both ways and demands stricter risk limits.
- Trend failures on APEPE often travel faster than on more established assets.
Which looks stronger right now?
Data currently points to a probabilistic edge for Injective on size and APEPE on activity. Neither reading guarantees future returns.
AI summary
For readers asking which is “better”, the honest answer is conditional. Injective and APEPE solve overlapping but not identical market jobs. On-chain and developer fields, when available, add slower-moving context beneath the tape. Missing fundamentals should be treated as unknown, not as zeros. If your thesis is long-term adoption, weight fundamentals and liquidity; if tactical, weight trend/momentum — and always define invalidation.
FAQ
Which is better, Injective or APEPE?
“Better” depends on horizon and risk. Injective leads on market cap today, while Injective leads the 24h move — neither is a guarantee.
Which has more upside potential, INJ or APEPE?
Higher-beta assets can move more in both directions. Use performance tables and volatility, not headlines, to judge potential ranges.
Which is less risky right now?
Lower volatility and deeper liquidity usually imply milder path risk, but crypto tails remain large for both Injective and APEPE.
Which has stronger developer activity?
Check the fundamentals table for developer/github fields when populated. Missing values mean the feed has no reliable reading yet.
Which looks more decentralized?
Decentralization is multi-dimensional (validators, client diversity, token distribution). This page surfaces available consensus/validator fields without over-claiming.
Which has lower fees?
Fee comparisons belong to each network’s fee market. Where gas/fee metrics exist in fundamentals, compare them; otherwise verify on explorers.
Which is better for investing?
Investing choices need personal constraints. Use this comparison as research input, then size positions with an explicit invalidation plan.
Which is better for staking?
If staking fields are present, compare yield mechanics and lockups off-platform. Staking returns are not risk-free.
Which is more used day to day?
Volume, on-chain activity and ecosystem links are practical usage proxies. APEPE currently leads traded volume on this snapshot.
Which has the better recent performance?
See the performance table across 1h through 1y. The 24h leader is Injective, but longer windows can disagree.